CAR T cell therapy targets key mutation driving rare blood cancers

A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, according to new research led by UCL and University of Oxford researchers. ...